Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immune Therapeutics Inc
(OP:
IMUN
)
N/A
UNCHANGED
Last Price
Updated: 12:27 PM EDT, Oct 18, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0930
Today's Range
N/A - N/A
52wk Range
0.0668 - 0.3300
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
September 14, 2023
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
August 29, 2023
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
Performance
More News
Read More
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
August 15, 2023
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging
October 18, 2022
Via
Benzinga
Why Are Statera Biopharma Shares Surging Today
April 28, 2022
Via
Benzinga
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
April 20, 2023
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
March 01, 2023
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
November 09, 2022
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
September 27, 2022
From
Immune Therapeutics, Inc.
Via
GlobeNewswire
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 28, 2022
Via
InvestorPlace
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
December 17, 2021
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.